FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation
esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study
AI Summary: The FDA has granted full approval for ziftomenib—a novel agent aimed at treating relapsed or refractory acute myeloid leukemia, especially in patients with NPM1 mutations. Backed by the KO‐MEN‐001 trial data, this decision marks a significant step forward for a patient group in dire need of new therapeutic options.
Related Stories
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 months
FDA rejects Corcept’s cortisol modulator triggering setback / 6 months
FDA approves Rucaparib for advanced prostate cancer / 6 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 6 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 7 months
FDA updates Sarepta gene therapy label with severe warnings / 7 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Diagnostics, Corporate Takeover, Research Funding, Supplements and look for the RSS link.
StackHealth Time Machine